You are here

  • Home
  • Archive
  • Volume 7, Issue 4
  • A simple scoring system predicted clinical progression in HIV patients receiving highly active antiretroviral therapy

Article Text

Article menu
Download PDFPDF
Clinical prediction guide
A simple scoring system predicted clinical progression in HIV patients receiving highly active antiretroviral therapy

https://doi.org/10.1136/ebm.7.4.128

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) J Infect Dis 185, 178; Lundgren JD, Mocroft A, Gatell JM, et al, for the EuroSIDA Study Group.. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study.. Jan 15;. :. –87.
    OpenUrlAbstract/FREE Full Text

    
 
 QUESTION: In patients with HIV who are receiving highly active antiretroviral therapy (HAART), does a scoring system predict clinical progression?

    Design

    Prognostic scoring system developed in 1 derivation cohort and validated in 2 cohorts of patients.

    Setting

    60 centres in Europe and Israel.

    Patients

    2027 patients (median age 37 y) formed the derivation set: inception cohort of participants in the EuroSIDA study who were ≥ 16 years of age and had started a protease inhibitor or non-nucleoside reverse-transcriptase inhibitor as part of a HAART antiretroviral regimen and had CD4 cell counts and viral loads measured within 6 months before starting HAART and ≥ 1 measurement after starting HAART. 2 cohorts of patients formed the validation set: 1946 patients in the EuroSIDA study who started HAART before recruitment to the study and 1442 patients from a clinic in Barcelona who had previously started HAART.

    Description of prediction guide

    Cox proportional hazards models were used to determine factors associated with clinical progression. The final prediction model comprised …

    View Full Text

    Footnotes

    • Sources of funding: European Commission BIOMED 1; Fifth Framework Program; GlaxoSmithKline, Roche, and Boehringer Ingelheim; Swiss Federal Office for Education and Science.

    • For correspondence: Dr J D Lundgren, Hvidovre University Hospital, Hvidovre, Denmark. jdl{at}cphiv.dk.